ImmuPharma (LON:IMM) Stock Price Up 4.9% – Should You Buy?

Shares of ImmuPharma plc (LON:IMMGet Free Report) shot up 4.9% during mid-day trading on Friday . The company traded as high as GBX 4.70 ($0.06) and last traded at GBX 3.67 ($0.04). 109,382,164 shares changed hands during trading, an increase of 245% from the average session volume of 31,664,631 shares. The stock had previously closed at GBX 3.50 ($0.04).

ImmuPharma Trading Up 4.9 %

The stock has a market cap of £15.30 million, a price-to-earnings ratio of -367.30 and a beta of 1.53. The company has a 50 day simple moving average of GBX 1.40 and a 200-day simple moving average of GBX 1.65.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

Further Reading

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.